A Pseudovirus Nanoparticle Displaying the Vaccinia Virus L1 Protein Elicited High Neutralizing Antibody Titers and Provided Complete Protection to Mice against Mortality Caused by a Vaccinia Virus Challenge
Open Access
Abstract
The recent worldwide incidence of mpox infection and concerns about future emerging variants of mpox viruses highlight the need for the development of a new generation of mpox vaccines. To achieve this goal, we utilized our norovirus S nanoparticle vaccine platform to produce and evaluate two pseudovirus nanoparticles (PVNPs), S-L1 and S-J1. These PVNPs displayed the L1 neutralizing antigen target of the vaccinia virus and a yet-untested J1 antigen of the mpox virus, respectively, with the aim of creating an effective nanoparticle-based mpox vaccine. Each self-assembled PVNP consists of an inner shell resembling the interior layer of the norovirus capsid and multiple L1 or J1 antigens on the surface. The PVNPs improved the antibody responses toward the displayed L1 or J1 antigens in mice, resulting in significantly greater L1/J1-specific IgG and IgA titers than those elicited by the corresponding free L1 or J1 antigens. After immunization with the S-L1 PVNPs, the mouse sera exhibited high neutralizing antibody titers against the vaccinia virus, and the S-L1 PVNPs provided mice with 100% protection against mortality caused by vaccinia virus challenge. In contrast, the S-J1 PVNPs induced low neutralizing antibody titers and conferred mice weak protective immunity. These data confirm that the L1 protein is an excellent vaccine target and that the readily available S-L1 PVNPs are a promising mpox vaccine candidate worthy of further development.Keywords
Funding Information
- National Center for Advancing Translational Sciences of the National Institutes of Health (2UL1TR001425)
- Blue Water Biotech, Inc. (2UL1TR001425)
This publication has 54 references indexed in Scilit:
- A bioengineered pseudovirus nanoparticle displaying SARS‐CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS‐CoV 2 challengeBiotechnology Journal, 2023
- Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicityNano Research, 2022
- UCSF ChimeraX: Structure visualization for researchers, educators, and developersProtein Science, 2020
- Heterologous expression of human norovirus GII.4 VP1 leads to assembly of T=4 virus-like particlesAntiviral Research, 2019
- A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challengeVaccine, 2010
- Proteome‐wide analysis of the serological response to vaccinia and smallpoxProteomics, 2007
- Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challengesVaccine, 2007
- A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boostVaccine, 2007
- Smallpox as a Biological WeaponJAMA, 1999
- A Myristylated Membrane Protein Encoded by the Vaccinia Virus L1R Open Reading Frame Is the Target of Potent Neutralizing Monoclonal AntibodiesVirology, 1995